Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0452 Transporter Info | ||||
| Gene Name | SLC6A2 | ||||
| Protein Name | Sodium-dependent noradrenaline transporter | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs12708954 | ||||
| Site of GPD | chr16:55697687 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>A | ||||
| Minor Allele Frequency | A=0.1853/928 (Global) | ||||
| Allele A | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Atomoxetine | Drug Info | Attention Deficit Disorder With Hyperactivity | Correlated with the increased drug response in patients (compare with allele C) | [ 1] | |
| Genetic Polymorphism | rs2242446 | ||||
| Site of GPD | chr16:55656513 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>A / C>T | ||||
| Minor Allele Frequency | C=0.2470/1237 (Global) | ||||
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Venlafaxine | Drug Info | Major Depressive Disorder | Correlated with the increased drug response in patients (compare with Genotypes CT + TT) | [ 2] | |
| Genotype TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| 3,4-Methylenedioxymethamphetamine | Drug Info | Posttraumatic Stress Disorder | Correlated with the decreased drug response (compare with genotypes CC + CT) | [ 3] | |
| Genetic Polymorphism | rs36029 | ||||
| Site of GPD | chr16:55662844 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>G | ||||
| Minor Allele Frequency | G=0.3978/1992 (Global) | ||||
| Genotype AA | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| 3,4-Methylenedioxymethamphetamine | Drug Info | Posttraumatic Stress Disorder | Correlated with the increased drug response in patients (compare with genotypes AG + GG) | [ 3] | |
| Genetic Polymorphism | rs3785143 | ||||
| Site of GPD | chr16:55661194 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>T | ||||
| Minor Allele Frequency | T=0.1048/525 (Global) | ||||
| Allele T | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Atomoxetine | Drug Info | Attention Deficit Disorder With Hyperactivity | Correlated with the decreased drug response in patients (compare with allele C) | [ 4] | |
| Genetic Polymorphism | rs5569 | ||||
| Site of GPD | chr16:55697923 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A / G>C | ||||
| Minor Allele Frequency | A=0.2334/1169 (Global) | ||||
| Allele A | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Methylphenidate | Drug Info | Attention Deficit Disorder With Hyperactivity | Irrelevant to the drug response in patients (compare with Allele G) | [ 5] | |
| Genotype GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Methylphenidate | Drug Info | Attention Deficit Disorder With Hyperactivity | Correlated with the increased drug response in patients (compare with genotypes AA + AG) | [ 6] | |
| Genetic Polymorphism | rs1861647 | ||||
| Site of GPD | chr16:55694494 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A / G>C | ||||
| Minor Allele Frequency | A=0.2384/1194 (Global) | ||||
| Genotype GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| 3,4-Methylenedioxymethamphetamine | Drug Info | Posttraumatic Stress Disorder | Correlated with the increased drug response (compare with genotypes AA + AG) | [ 3] | |
| References | |||||
| 1 | A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology. 2009 Aug;34(9):2135-42. | ||||
| 2 | Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. Am J Psychiatry. 2017 May 1;174(5):468-475. | ||||
| 3 | No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA. Eur J Clin Pharmacol. 2018 Mar;74(3):275-283. | ||||
| 4 | Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J Neural Transm (Vienna). 2013 Jul;120(7):1127-33. | ||||
| 5 | Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD. Psychiatry Res. 2011 Apr 30;186(2-3):338-44. | ||||
| 6 | Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder. Int Clin Psychopharmacol. 2011 Mar;26(2):107-13. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.